EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines
Maryam Latarani(The Open University), Francesco Crea(The Open University)
Cited by 4
Related Papers
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
|Clinical Epigenetics|2016|78
EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2024|1